Abstract 1675P
Background
Adjuvant hormonal therapy (AHT) is integral to breast cancer management but often severely impacts the quality of life (QoL), especially concerning sexual functioning and psychological well-being. This study evaluates the effects of AHT on the sexual and global QoL of young breast cancer survivors.
Methods
This cross-sectional study was conducted at two cancer centers within Cairo, Egypt, involving 644 young breast cancer patients. The European Organization for Research and Treatment of Cancer EORTC QLQ - BR45 questionnaire was employed to assess the impact of AHT on sexual and global QoL. Data analysis encompassed demographic factors, treatment regimens, duration of therapy, functional and symptomatic scales of the questionnaire.
Results
The participants' median age was 41 years (range: 25-45), the primary AHT consisted of Tamoxifen + LHRH analogues (55.4%). there was a notable decrease in sexual enjoyment, with 50.7% of participants reporting no sexual activity in the past month. Among those who were sexually active, only 7.1% reported high enjoyment post-treatment compared to 31.5% pre-treatment. Additionally, 48.1% of patients experienced a complete lack of sexual desire post-treatment, while 38% expressed a significant need for psychological support. Analysis of the EORTC QLQ - BR45 questionnaire revealed Sexual Enjoyment Score: 52.9, Body image score 59.3, and Endocrine side effect score 49.4.
Conclusions
The findings reveal a profound impact of AHT on both the sexual and overall QoL among young breast cancer patients. The significant decline in sexual enjoyment and desire, coupled with a substantial need for psychological support, underscores the necessity for integrated care strategies that address the comprehensive health challenges faced by young breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11